Investigational Drug Information for Vistusertib
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Vistusertib?
Vistusertib is an investigational drug.
There have been 14 clinical trials for Vistusertib.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2015.
The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Breast Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Samsung Medical Center.
There are one hundred and fourteen US patents protecting this investigational drug and one international patent.
Summary for Vistusertib
| US Patents | 114 |
| International Patents | 1,344 |
| US Patent Applications | 535 |
| WIPO Patent Applications | 398 |
| Japanese Patent Applications | 151 |
| Clinical Trial Progress | Phase 2 (2015-10-01) |
| Vendors | 65 |
Recent Clinical Trials for Vistusertib
| Title | Sponsor | Phase |
|---|---|---|
| Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) | National Cancer Institute (NCI) | Phase 1 |
| Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy | Samsung Medical Center | Phase 2 |
| Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy | Samsung Medical Center | Phase 2 |
Clinical Trial Summary for Vistusertib
Top disease conditions for Vistusertib
Top clinical trial sponsors for Vistusertib
US Patents for Vistusertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Vistusertib | See Plans and Pricing | Low, immune enhancing, dose mtor inhibitors and uses thereof | Novartis AG (Basel, CH) | See Plans and Pricing |
| Vistusertib | See Plans and Pricing | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KuDOS Pharmaceuticals Limited (London, GB) | See Plans and Pricing |
| Vistusertib | See Plans and Pricing | 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]- pyrimidin-5 (1h)-one, salts thereof and methods of using the same in combination therapy | Oncoceutics, Inc. (Philadelphia, PA) | See Plans and Pricing |
| Vistusertib | See Plans and Pricing | Heterocyclic estrogen receptor modulators and uses thereof | Genentech, Inc. (South San Francisco, CA) | See Plans and Pricing |
| Vistusertib | See Plans and Pricing | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases | ZHEJIANG DTRM BIOPHARMA CO. LTD. (Hangzhou, CN) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Vistusertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Vistusertib | Australia | AU2014348657 | 2033-11-13 | See Plans and Pricing |
| Vistusertib | Australia | AU2017245411 | 2033-11-13 | See Plans and Pricing |
| Vistusertib | Australia | AU2019246853 | 2033-11-13 | See Plans and Pricing |
| Vistusertib | Brazil | BR112016010716 | 2033-11-13 | See Plans and Pricing |
| Vistusertib | Canada | CA2929181 | 2033-11-13 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
